Get the Stockscreener App
1.88
0.00%
0.00
After Hours:
1.88
Essa Pharma Inc stock is traded at $1.88, with a volume of 153.04K.
It is up +0.00% in the last 24 hours and up +8.67% over the past month.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
See More
Previous Close:
$1.88
Open:
$1.88
24h Volume:
153.04K
Relative Volume:
0.71
Market Cap:
$83.45M
Revenue:
-
Net Income/Loss:
$-28.54M
P/E Ratio:
-2.9375
EPS:
-0.64
Net Cash Flow:
$-22.72M
1W Performance:
+0.00%
1M Performance:
+8.67%
6M Performance:
+9.30%
1Y Performance:
-63.42%
1-Day Range:
$1.88
$1.89
1-Week Range:
$1.87
$1.89
52-Week Range:
$1.40
$7.88
Essa Pharma Inc Stock (EPIX) Company Profile
Name
Essa Pharma Inc
Sector
Industry
Phone
(778) 331-0962
Address
SUITE 720, VANCOUVER, BC
Compare EPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPIX
Essa Pharma Inc
|
1.88 | 83.36M | 0 | -28.54M | -22.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-04-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-04-21 | Initiated | Piper Sandler | Overweight |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-25-19 | Initiated | Oppenheimer | Outperform |
View All
Essa Pharma Inc Stock (EPIX) Latest News
Is it the right time to buy ESSA Pharma Inc. stockCapitalize on fast-growing stocks today - jammulinksnews.com
Is ESSA Pharma Inc. a growth stock or a value stockBreakout profit opportunities - jammulinksnews.com
Why is ESSA Pharma Inc. stock attracting strong analyst attentionCapitalize on emerging market opportunities - jammulinksnews.com
How many analysts rate ESSA Pharma Inc. as a “Buy”Maximize portfolio returns with smart trading - jammulinksnews.com
What are the technical indicators suggesting about ESSA Pharma Inc.Outstanding capital growth - jammulinksnews.com
What are the latest earnings results for ESSA Pharma Inc.Discover high-impact stocks for growth - jammulinksnews.com
What is the dividend policy of ESSA Pharma Inc. stockBuild your wealth with consistent stock growth - jammulinksnews.com
What makes ESSA Pharma Inc. stock price move sharplyUnlock powerful portfolio optimization tools - jammulinksnews.com
How does ESSA Pharma Inc. generate profit in a changing economyAchieve consistent profits with expert advice - jammulinksnews.com
Can volume confirm reversal in ESSA Pharma Inc.Buy Strategy Review With Performance Summary - Newser
What analysts say about ESSA Pharma Inc. stockExplosive market performance - jammulinksnews.com
What are ESSA Pharma Inc. company’s key revenue driversTriple-digit returns - jammulinksnews.com
Should I hold or sell ESSA Pharma Inc. stock in 2025Boost your returns with professional guidance - jammulinksnews.com
Does ESSA Pharma Inc. stock perform well during market downturnsInvest confidently with real-time market updates - jammulinksnews.com
ESSA Pharma Inc. Stock Analysis and ForecastTriple-digit return opportunities - jammulinksnews.com
Will ESSA Pharma Inc. benefit from macro trendsWeekly High Conviction Trade Setup Analysis - Newser
Will a bounce in ESSA Pharma Inc. offer an exitForecast Model for Intraday Buy Signals - Newser
ESSA Pharma (EPIX) Expected to Announce Earnings on Monday - Defense World
What machine learning models say about ESSA Pharma Inc.AI Intraday Market Movement Prediction Tool - Newser
Chart based analysis of ESSA Pharma Inc. trendsMarket Opportunity Tracker for Swing Traders - Newser
ESSA Pharma EPIX Q3 2025 Earnings Preview Uncertain Outlook Amid Acquisition and Clinical Developments - AInvest
ESSA Pharma Inc. stock chart pattern explainedFree Market Momentum and Signal Alerts - Newser
How ESSA Pharma Inc. stock performs during market volatilityFree Weekly Return Pick Forecast Reports - Newser
ESSA Pharma Announces Tax Implications of Cash Distribution - TipRanks
ESSA Pharma to be Acquired by XenoTherapeutics for $177 Million. - AInvest
Using fundamentals and technicals on ESSA Pharma Inc.Historical Stock Summary and ROI Review - Newser
Using data tools to time your ESSA Pharma Inc. exitFree Chart Breakout Buy Signal Detection - Newser
ESSA Pharma Inc. Recovery Gathers Momentum on Chart SignalsEarly Entry Tips With Low Risk Zone Shared - beatles.ru
Live market analysis of ESSA Pharma Inc.AI Stock Movement Forecast with Accuracy - Newser
Published on: 2025-07-29 23:35:22 - metal.it
ESSA Pharma Inc. Stock Support and Resistance Levels You Should KnowYearly Trend Summary and Opportunity Breakdown - Newser
Why ESSA Pharma Inc. stock attracts strong analyst attentionAI Screener for Daily Stock Forecast - Newser
Is ESSA Pharma Inc. stock overvalued or undervaluedFree Stock Watchlist For Fast Growth - jammulinksnews.com
When is ESSA Pharma Inc. stock expected to show significant growthRecord-breaking capital gains - jammulinksnews.com
Essa Pharma Inc Stock (EPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):